EAN 2021: Real-World Follow-Up Confirms Favorable Risk-Benefit of Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis
Relapse rates diminished and patient-reported outcomes improved or remained stable
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.